Pharmacology & Pharmacodynamics

We can provide various xenograft models to test the effectiveness of drugs according to our clients' requirements. Typical diseases include head and neck cancer, lung cancer, breast cancer, gastric cancer and pancreatic cancer, with mice, rats and hamsters as test subjects. We are committed to providing clients with mature orthotopic models for evaluating the in vivo efficacy of ADC, completing the modeling and feeding of model animals in an AAALAC-accredited environment, and relevant pharmacodynamic evaluation experiments standards of a GLP level.

We can provide various animal models (including renal failure model, anemia animal model, gastric acid secretion animal model, and gastric ulcer model) to test drug effectiveness according to client needs. We can conduct tests on typical digestive system diseases, including gastric acid secretions, gastric ulcers, and renal failure, using rats as subjects.

In the field of metabolic diseases, we are proud of our portfolio of stable and effective animal models, especially those for Non-alcoholic Fatty Liver Disease (NAFLD). Though popular recently, they still lack effective drug treatment.

At present, as the pathogenesis of inflammatory and immunological diseases is unclear, there are few effective therapeutic drugs available in clinical practice. In such a context, the appropriate preclinical research techniques and models are required to help companies and researchers further develop and evaluate new drugs. Our Preclinical Pharmacodynamics Department has been deeply involved in this field for years, developing reliable animal-based efficacy evaluation models aimed at different targets and pathways, thus facilitating the clinical transformation of new drugs.

Our Pharmacodynamics Department is proud of its multiple nervous system models based on anti-depressants, anti-Alzheimer's drugs, sedative-hypnotic and anti-anxiety drugs, analgesics, anti-convulsants, anti-Parkinson's drugs, and anti-schizophrenia drugs. Those models can effectively evaluate Type-1 innovative drugs at the molecular and cellular level, as well as ex vivo, and in vivo. The Department's advanced Cognition Wall Discrimination learning ensures uninterrupted tracking to determine changes in memory function in double transgenic mice during tearly-stage Alzheimer's disease, and eliminates the disadvantages of the Morris water maze (MWM) in stress interference and short-time tests.